TRIP.C is starting another leg up on Brazil expansion news

TRIP had a major news release today, having its psychedelic products authorized for import to Brazil. The stock has consolidated well and is forming a Double Bottom ( bullish biased) pattern on the daily chart . Promotional campaign is under way. I am in at .495.


Red Light Holland iMicrodose Pack Receives Authorization for the First Legal Import and Sale of Psilocybin Truffles to Brazil

Anvisa, The Brazilian Health Regulatory Agency has granted a permit to import the Company's iMicrodose Pack by way of the Country's 'named patient import process' for prescribed medical use

Toronto, Ontario--(Newsfile Corp. - February 25, 2021) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is extremely pleased to announce that Anvisa, Brazil's National Health Regulatory Agency, has granted authorization for the Company's iMicrodose packs, which contain 15g of Psilocybin Truffles, to be legally imported to Brazil via the 'named patient import process' for prescribed medical patient use.

"We are grateful for our collaborative relationship with Disruptive Pharma who worked closely with the Brazilian Health Regulatory Agency to secure authorization to import Red Light Holland's iMicrodose packs, with our natural-occurring branded Psilocybin Truffles, to be imported and sold in Brazil for Medical use, as our branded iMicrodose packs have officially been prescribed by a doctor to a patient in Brazil," said Todd Shapiro, CEO and Director of Red Light Holland. "This is a monumental day for the Company, and we are so proud to be a part of providing legal access of psilocybin to Brazil and for the first time having our product prescribed by a physician for medical use."

Red Light Holland's iMicrodose packs have been shipped to Disruptive Pharma's MyPharma2Go logistics hub in the Netherlands to start their journey to Brazil. Once landed in Brazil, MyPharma2Go is expected to deliver the iMicrodose packs to a Brazilian patient as they have been pre-prescribed by a physician, before the end of March 2021.

This approval and shipment represent a significant advancement in opening the legal and medically approved market for psilocybin in Brazil, a country with a population of over 200 million people. Shapiro added: "This early process working alongside Disruptive Pharma's MyPharma2Go.com, a large Brazilian online pharmaceutical and supplement distributor, has been an absolute pleasure and one we are thankful for. We are pleased to do our part to potentially be a part of positive change in Brazil, and to steal a line from Neil Armstrong: This is one micro step for man, one macro leap for mankind."

Red Light Holland and Disruptive Pharma continue to work towards finalizing their proposed joint venture structure and agreement, as previously disclosed in the Company's news release dated December 14, 2020. In consideration for Disruptive Pharma having met these initial milestones, the Company has agreed to issue to Disruptive Pharma , 3,000,000 common share purchase warrants, each warrant is exercisable into one common share of the Company at a price of $0.50 per share for a period of 2 years. 750,000 of these warrants have vested immediately based on Disruptive Pharma having fulfilled these milestones, the balance vest upon future milestones being met. These warrants and any underlying shares issued upon exercise, are subject to a statutory hold period of 4 months and 1 day.

Full-time market researcher. Not an investment advisor. Ideas are not a recommendation to buy or sell securities. For intraday alerts, weekly sector-by-sector analysis, watchlists and more, get our Premium Subscription at http://agstockpicks.com.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.